291 related articles for article (PubMed ID: 36240540)
1. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
[TBL] [Abstract][Full Text] [Related]
2. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
Metcalfe J; Bacchetti P; Esmail A; Reckers A; Aguilar D; Wen A; Huo S; Muyindike WR; Hahn JA; Dheda K; Gandhi M; Gerona R
BMC Infect Dis; 2021 Jan; 21(1):99. PubMed ID: 33482745
[TBL] [Abstract][Full Text] [Related]
4. A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis.
Köhler N; Karaköse H; Grobbel HP; Hillemann D; Andres S; König C; Kalsdorf B; Brehm TT; Böttcher L; Friesen I; Hoffmann H; Strelec D; Schaub D; Peloquin CA; Schmiedel S; Decosterd LA; Choong E; Wicha SG; Aarnoutse RE; Lange C; Sánchez Carballo PM
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004523
[TBL] [Abstract][Full Text] [Related]
5. Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd LA; Mercier T; Ternon B; Cruchon S; Guignard N; Lahrichi S; Pesse B; Rochat B; Burger R; Lamoth F; Pagani JL; Eggimann P; Csajka C; Choong E; Buclin T; Widmer N; André P; Marchetti O
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122160. PubMed ID: 32891946
[TBL] [Abstract][Full Text] [Related]
6. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
Kengo A; Nabeemeeah F; Denti P; Sabet R; Okyere-Manu G; Abraham P; Weisner L; Mosala MH; Tshabalala S; Scholefield J; Resendiz-Galvan JE; Martinson NA; Variava E
Antimicrob Agents Chemother; 2024 May; 68(5):e0158323. PubMed ID: 38597667
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.
Prahl JB; Lundqvist M; Bahl JM; Johansen IS; Andersen ÅB; Frimodt-Møller N; Cohen AS
APMIS; 2016 Nov; 124(11):1004-1015. PubMed ID: 27546025
[TBL] [Abstract][Full Text] [Related]
8. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
9. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
Kim HJ; Seo KA; Kim HM; Jeong ES; Ghim JL; Lee SH; Lee YM; Kim DH; Shin JG
J Pharm Biomed Anal; 2015 Jan; 102():9-16. PubMed ID: 25218029
[TBL] [Abstract][Full Text] [Related]
10. Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Wu L; Ye Z; Liu H; Guo H; Lin J; Zheng L; Chu N; Liu X
J Pharm Biomed Anal; 2020 Feb; 180():113076. PubMed ID: 31896523
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
Zheng X; Jongedijk EM; Hu Y; Kuhlin J; Zheng R; Niward K; Paues J; Xu B; Davies Forsman L; Schön T; Bruchfeld J; Alffenaar JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1158():122397. PubMed ID: 33091676
[TBL] [Abstract][Full Text] [Related]
12. Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk.
Zuma P; Joubert A; van der Merwe M; Norman J; Waitt C; Court R; Loveday M; Castel S; Wiesner L
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123489. PubMed ID: 36215877
[TBL] [Abstract][Full Text] [Related]
13. Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Cho HJ; Lim YJ; Kim J; Koh WJ; Song CH; Kang MW
BMC Infect Dis; 2020 Jan; 20(1):81. PubMed ID: 31996142
[TBL] [Abstract][Full Text] [Related]
14. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
15. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
18. Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots.
Herrera-Pérez IG; Rodríguez-Báez AS; Ortiz-Álvarez A; Velarde-Salcedo R; Arriaga-García FJ; Rodríguez-Pinal CJ; Romano-Moreno S; Milán-Segovia RDC; Medellín-Garibay SE
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123801. PubMed ID: 37453389
[TBL] [Abstract][Full Text] [Related]
19. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
Kuhlin J; Sturkenboom MGG; Ghimire S; Margineanu I; van den Elsen SHJ; Simbar N; Akkerman OW; Jongedijk EM; Koster RA; Bruchfeld J; Touw DJ; Alffenaar JC
Clin Mass Spectrom; 2019 Sep; 14 Pt A():34-45. PubMed ID: 34934812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
